Please login to the form below
Amgen announces 380 US job cuts
Amgen is to cut 380 R&D jobs in the US as the biotechnology company aims to streamline its operations
Amgen is to cut 380 R&D jobs in the US as the biotechnology company aims to streamline its operations.
Mary Klem, director of media relations at the company, said the job losses were "targeted and strategic", with no particular therapy area affected or sites to be shut down.
Jobs will go at research facilities in Thousand Oaks and San Francisco in California, as well as in Seattle and Massachusetts. Cuts are also expected in the UK.
Klem said: "We have lots of molecules moving into later stages of development, which means more expensive stages of development."
Amgen also announced former Bristol-Myers Squibb (BMS) senior vice president, commercial operations, Tony Hooper as the company's executive vice president, global commercial operations, effective October 26.
Hooper spent 16 years at BMS where his roles included running the BMS commercial business in North America, Asia, Middle East, Africa, South America and Europe.
He said: "It's a privilege to join Amgen, a company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses."
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Recognising HIV Vaccine Awareness Day
- Almirall and Evotec team up in multi-target dermatology alliance
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Scientists discover new approach to treat brain tumours
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
- Part 1 of the Medscape video interview series
- NHS England appoints Chris Hopson as its new chief strategy officer
- Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month
- Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children
- AbbVie submits Parkinson’s disease therapy to FDA
- When is an agency not an agency?
- Jardiance is first diabetes drug to improve CV outcomes
- Roche shares new positive Ocrevus data for MS patients
- EMA reviewing Biogen’s potential Alzheimer’s drug for use in the EU
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- How to plan, execute and refine an excellent congress experience
- GPs will play a pivotal role in integrated care
PMHub
Origins Insights
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...
Latest intelligence
- When is an agency not an agency?
- The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
